Tag: GlobeNewswire

Dipti Vachani appointed as Chief Executive Officer
Signed multi-year license renewals with Charter and TCL
Reiterate confidence in long-term $600 million annual revenue outlook

SAN JOSE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”), the technology company pioneering foundational innovations that shape how the world computes, connects and experiences entertainment, today announced financial results for the third quarter ended September 30, 2026.

“I am honored to join Adeia at such an exciting time as AI is driving innovation in both media and semiconductors, and Adeia’s foundational technologies are at the heart of these trends,” said Dipti Vachani, chief executive officer of Adeia. “Our third quarter results reflected strong deal activity with eight license agreements signed across Pay-TV, consumer electronics, e-commerce and social media. Those deals included significant renewals with long-time customers Charter and TCL and four new customers during the quarter. We are on target to achieve our long-term annual revenue outlook of $600 million and we remain excited about our future.”

Vachani continued, “I want to thank the Board for their confidence in me and Paul Davis for his support during this transition. Through my nearly 30 years of experience in the semiconductor space, I have a deep understanding of the technology, the ecosystem and the barriers to scale that Adeia customers are experiencing. With my proven track record, coupled with our talented team of innovators and extensive patent portfolios, I am confident that we have all the ingredients to grow and expand our business.”

“We are pleased with the progress that we have made to date as our pipeline remains strong and is growing,” said Keith Jones, chief financial officer. “As we approach the end of the year, our revenue could be impacted by the ultimate timing of executing a select few deals. We remain confident in our ability to achieve the high-end of our revenue guidance range for 2026. However, we felt it prudent to adjust the range to reflect the potential impact to the extent certain of these deals are executed beyond the end of the year.”

Third Quarter Financial Highlights

• Revenue was $80.2 million as compared to $96.1 million in the second quarter of 2026
• GAAP diluted earnings per share (EPS) was $0.02 and non-GAAP diluted EPS was $0.21
• GAAP net income was $2.3 million and adjusted EBITDA was $36.9 million
• Cash flow from operations was $5.1 million
• Paid down $6.1 million on our term loan
• Ended the quarter with $127.7 million in cash, cash equivalents, and marketable securities

Business Highlights

• Signed eight license agreements, including with four new customers in the quarter, for access to our media portfolio:
  • A multi-year renewal with Charter, the largest Pay-TV and broadband provider in the U.S.
  • A multi-year renewal with TCL, one of the world’s largest manufacturers of connected TVs
  • A new long-term license agreement with Fanatics, a leading sports apparel e-commerce company
  • New license agreements with a social media company and a consumer electronics company, as well as three other license agreements with Pay-TV providers

Capital Allocation

During the quarter, the Company made $6.1 million in principal payments towards its term loan, bringing the outstanding balance to $386.5 million as of September 30, 2026.  

On September 14, 2026, the Company distributed $5.5 million to stockholders of record on August 24, 2026, for a quarterly cash dividend of $0.05 per share of common stock.

The Board of Directors declared a dividend of $0.05 per share, payable on December 14, 2026, to stockholders of record on November 23, 2026.

Financial Outlook

The Company is updating its full year 2026 outlook as follows:

		2026 GAAP Outlook						2026 Non-GAAP Outlook
Category (in millions, except for tax rate)		Updated			Prior			Updated			Prior
Revenue		$375.0 − 415.0			$395.0 − 435.0			$375.0 − 415.0			$395.0 − 435.0
Operating expenses (1)		$283.0 − 289.0			$295.0 − 305.0			$176.0 − 180.0			$184.0 − 192.0
Interest expense		$32.0 − 34.0			$34.0 − 36.0			$32.0 − 34.0			$34.0 − 36.0
Other income		$6.0 − 7.0			$5.5 − 6.5			$6.0 − 7.0			$5.5 − 6.5
Tax rate		20%			20%			21%			21%
Net income (2)		$52.8 − 79.2			$57.2 − 80.4			$136.7 − 164.3			$144.2 − 168.7
Adjusted EBITDA (2)		N/A			N/A			$201.1 − 237.1			$213.4 − 245.4
Diluted shares outstanding		113.5 − 114.5			114.0 − 115.0			113.5 − 114.5			114.0 − 115.0

⁽¹⁾ _{See tables for reconciliation of GAAP to non-GAAP operating expenses.}
⁽²⁾ _{See tables for reconciliation of GAAP net income to (i) non-GAAP net income and (ii) adjusted earnings before interest expense, income taxes, depreciation and amortization (adjusted EBITDA).}

Conference Call Information

The Company will hold its third quarter 2026 earnings conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) on Monday, November 2, 2026. To access the call in the U.S., please dial +1 (888) 660-6411, and for international callers, dial +1 (929) 203-0849. All participants should dial in 15 minutes prior to the start of the conference call. The Company also suggests utilizing the webcast link to access the live call and the replay at Q3 2026 Earnings Call Webcast. A live and replay webcast will be available on the Adeia Investor Relations website at https://investors.adeia.com.   

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on information available to the Company as of the date hereof, as well as the Company’s current expectations, assumptions, estimates and projections that involve risks and uncertainties. In this context, forward-looking statements often address expected future business, financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” “target,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond the Company’s control, and are not guarantees of future results.

Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements and caution must be exercised in relying on forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: the Company’s ability to implement its business strategy; the Company’s ability to enter into new and renewal license agreements with customers on favorable terms; the length of time it takes to enter into license agreements; the Company’s ability to retain and hire key personnel; uncertainty as to the long-term value of the Company’s common stock; legislative, regulatory and economic developments affecting the Company’s business; general economic and market developments and conditions; the Company’s ability to grow and expand its patent portfolios; the Company’s success in litigation, arbitration and administrative proceedings to defend our IP rights and our licensing practice and the costs associated with such defense; changes in technology and development of new technology in the industries in which in which the Company operates; the evolving legal, regulatory and tax regimes under which the Company operates; unforeseen liabilities and expenses; risks associated with the Company’s indebtedness; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, natural disasters and global health pandemics, each of which may have an adverse impact on the Company’s business, results of operations, and financial condition. These risks, as well as other risks associated with the Company’s business, are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. While the list of factors presented here is, and the list of factors presented in the Company’s filings with the SEC are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements.

Causes of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, failure to complete licensing arrangements on anticipated terms and timeline, failure to prevail in litigation we may bring against third parties, financial loss, legal liability to third parties and similar risks, and failure to attract or retain employees, any of which could have a material adverse effect on the Company’s consolidated financial condition, results of operations, liquidity or trading price of common stock. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

About Adeia Inc.

Adeia Inc. (Nasdaq: ADEA) develops foundational innovations that shape how the world computes, connects and experiences entertainment. Its inventions span a broad range of semiconductor and media technologies, including 3D interconnect (hybrid bonding) and advanced thermal management for AI datacenters, as well as content discovery, personalization, and streaming. These inventions are licensed to leaders across the chip design and manufacturing, consumer electronics, automotive, digital entertainment, and e-commerce industries. Adeia’s innovations enable more powerful and efficient products, and more immersive, personalized experiences across billions of devices worldwide. Learn more at www.adeia.com.

Non-GAAP Financial Measures

In addition to disclosing financial results calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), the Company’s earnings release contains non-GAAP financial measures adjusted, where applicable, for either one-time or ongoing non-cash acquired intangibles amortization charges, costs related to actual or planned business combinations including transaction fees, integration costs, severance, facility closures, and retention bonuses, separation costs, all forms of stock-based compensation, leadership transition costs, loss on debt extinguishment, expensed debt refinancing costs, impairment of intangible assets, impact of certain foreign currency adjustments, discontinued operations and related tax effects. In addition, adjusted EBITDA adjusts for recurring charges of interest expense, income taxes, depreciation and amortization. Management believes that the non-GAAP measures used in this release provide investors with important perspectives on the Company’s ongoing business and financial performance and are helpful to provide investors with an understanding of our core operating results reflecting our normal business operations. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP. Our use of non-GAAP financial measures has certain limitations in that the non-GAAP financial measures we use may not be directly comparable to those reported by other companies. For example, the terms used in this press release, such as EBITDA margin, which is defined as EBITDA as a percentage of revenue, adjusted EBITDA, adjusted EBITDA margin, non-GAAP operating expenses, non-GAAP net income and non-GAAP diluted earnings per share (EPS) do not have a standardized meaning. Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of our performance in relation to other companies. We seek to compensate for the limitation of our non-GAAP presentation by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached hereto. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. All financial data is presented on a GAAP basis except where the Company indicates its presentation is on a non-GAAP basis.   

Set forth below are reconciliations of the Company’s reported and forecasted GAAP to non-GAAP financial metrics.

Investor Contact:

Chris Chaney
Vice President, Investor Relations
IR@adeia.com

– Tables Follow – SOURCE: ADEIA INC. ADEA
ADEIA INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share amounts) (unaudited)
		Three Months Ended								Nine Months Ended
		September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
Revenue		$	80,193			$	87,339			$	281,082			$	260,744
Operating expenses:
Research and development			18,674				16,040				55,217				48,364
Selling, general and administrative			29,002				24,920				89,816				85,481
Amortization expense			16,291				14,175				48,311				42,427
Litigation expense			7,182				5,195				18,489				18,223
Total operating expenses			71,149				60,330				211,833				194,495
Operating income			9,044				27,009				69,249				66,249
Interest expense			(8,051	)			(10,054	)			(24,632	)			(30,919	)
Other income and expense, net			1,785				1,476				5,144				4,622
Income before income taxes			2,778				18,431				49,761				39,952
Provision for income taxes			511				9,603				7,355				2,588
Net income		$	2,267			$	8,828			$	42,406			$	37,364
Net income per share:
Basic		$	0.02			$	0.08			$	0.39			$	0.34
Diluted		$	0.02			$	0.08			$	0.37			$	0.33
Weighted average number of shares used in per share calculations:
Basic			110,319				109,421				110,018				108,735
Diluted			114,254				112,823				114,288				112,676

ADEIA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited)
		September 30,				December 31,
		2026				2025
ASSETS
Current assets:
Cash and cash equivalents		$	64,308			$	73,136
Marketable securities			63,439				63,597
Total cash, cash equivalents, and marketable securities			127,747				136,733
Accounts receivable, net			22,444				28,631
Unbilled contracts receivable			144,869				129,829
Other current assets			10,185				8,765
Total current assets			305,245				303,958
Long-term unbilled contracts receivable			41,562				49,499
Property and equipment, net			6,734				6,113
Operating lease right-of-use assets			7,286				8,177
Intangible assets, net			272,108				303,456
Goodwill			313,660				313,660
Other long-term assets			60,569				54,440
Total assets		$	1,007,164			$	1,039,303
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable		$	7,515			$	4,827
Accrued liabilities			24,334				34,250
Current portion of long-term debt, net			20,985				20,975
Deferred revenue			30,926				19,726
Total current liabilities			83,760				79,778
Deferred revenue, less current portion			49,989				49,975
Long-term debt, net			359,789				397,479
Noncurrent operating lease liabilities			8,229				8,734
Long-term income tax payable			7,774				7,273
Other long-term liabilities			14,857				15,523
Total liabilities			524,398				558,762
Commitments and contingencies
Stockholders’ equity:
Preferred stock			—			—
Common stock			133				128
Additional paid-in capital			717,329				685,992
Treasury stock at cost			(352,208	)			(297,778	)
Accumulated other comprehensive income (loss)			(478	)			60
Retained earnings			117,990				92,139
Total stockholders’ equity			482,766				480,541
Total liabilities and stockholders’ equity		$	1,007,164			$	1,039,303

ADEIA INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)
		Nine Months Ended
		September 30, 2026				September 30, 2025
Cash flows from operating activities:
Net income		$	42,406			$	37,364
Adjustments to reconcile net income to net cash from operating activities:
Depreciation of property and equipment			1,472				1,476
Amortization of intangible assets			48,311				42,427
Stock-based compensation expense			29,854				25,627
Deferred income tax and other			(5,662	)			2,256
Amortization of debt issuance costs			2,587				2,495
Other			(160	)			(334	)
Changes in operating assets and liabilities:
Accounts receivable			6,187				4,015
Unbilled contracts receivable			(7,103	)			3,347
Other assets			(996	)			(12,900	)
Accounts payable			2,692				(4,285	)
Accrued and other liabilities			(10,587	)			(1,615	)
Deferred revenue			9,244				(1,785	)
Net cash provided by operating activities			118,245				98,088
Cash flows from investing activities:
Purchases of property and equipment			(2,097	)			(1,216	)
Purchases of intangible assets			(14,992	)			(6,100	)
Purchases of short-term investments			(27,320	)			(46,256	)
Proceeds from sales of investments			—				996
Proceeds from maturities of investments			27,105				18,200
Net cash used in investing activities			(17,304	)			(34,376	)
Cash flows from financing activities:
Principal payments on debt agreements			(40,267	)			(39,267	)
Payments of dividends			(16,555	)			(16,328	)
Proceeds from employee stock purchase program and exercise of stock options			1,483				1,405
Repurchases of common stock			(34,419	)			(20,931	)
Repurchases of common stock for tax withholdings on equity awards			(20,011	)			(11,326	)
Net cash used in financing activities			(109,769	)			(86,447	)
Net decrease in cash and cash equivalents			(8,828	)			(22,735	)
Cash and cash equivalents at beginning of period			73,136				78,825
Cash and cash equivalents at end of period		$	64,308			$	56,090

ADEIA INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share amounts) (unaudited)
Net income
		Three Months Ended								Nine Months Ended
		September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
GAAP net income		$	2,267			$	8,828			$	42,406			$	37,364
Adjustments to GAAP net income:
Stock-based compensation expense:
Research and development			2,065				1,488				5,715				4,144
Selling, general and administrative			8,576				7,195				24,139				21,483
Amortization expense			16,291				14,175				48,311				42,427
Transaction costs recorded in selling, general and administrative			—				23				—				1,177
Leadership transition and other related costs recorded in selling, general and administrative			205				—				402				—
Separation and other related costs recorded in selling, general and administrative (1)			216				334				6,328				6,713
Total operating expenses adjustments			27,353				23,215				84,895				75,944
Non-GAAP tax adjustment (2)			(5,817	)			24				(20,923	)			(24,069	)
Non-GAAP net income		$	23,803			$	32,067			$	106,378			$	89,239
Diluted earnings per share
		Three Months Ended								Nine Months Ended
		September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
GAAP diluted earnings per share		$	0.02			$	0.08			$	0.37			$	0.33
Adjustments to GAAP diluted earnings per share:
Stock-based compensation expense:
Research and development			0.02				0.01				0.05				0.04
Selling, general and administrative			0.08				0.06				0.21				0.19
Amortization expense			0.14				0.13				0.42				0.38
Transaction costs recorded in selling, general and administrative			—				—				—				0.01
Leadership transition and other related costs recorded in selling, general and administrative			—				—				—
Separation and other related costs recorded in selling, general and administrative (1)			—				—				0.06				0.05
Total operating expenses adjustments			0.24				0.20				0.74				0.67
Non-GAAP tax adjustment (2)			(0.05	)			—				(0.18	)			(0.21	)
Non-GAAP diluted earnings per share		$	0.21			$	0.28			$	0.93			$	0.79

⁽¹⁾ _{Represents separation and related costs that were incurred subsequent to the separation on October 1, 2022, including expenses incurred on a transitional basis under a contract shared with Xperi Inc.}
⁽²⁾ _{The provision for income taxes is adjusted to reflect the net income tax effects of the various non-GAAP pretax adjustments.}

ADEIA INC. GAAP NET INCOME TO ADJUSTED EBITDA RECONCILIATION (in thousands) (unaudited)
		Three Months Ended								Nine Months Ended
		September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
GAAP net income		$	2,267			$	8,828			$	42,406			$	37,364
Adjustments to GAAP net income:
Stock-based compensation expense:
Research and development			2,065				1,488				5,715				4,144
Selling, general and administrative			8,576				7,195				24,139				21,483
Transaction costs recorded in selling, general and administrative			—				23				—				1,177
Leadership transition and other related costs recorded in selling, general and administrative			205				—				402				—
Separation and other related costs recorded in selling, general and administrative (1)			216				334				6,328				6,712
Amortization expense			16,291				14,175				48,311				42,427
Depreciation expense			500				479				1,472				1,476
Interest expense			8,051				10,054				24,632				30,919
Other income and expense, net			(1,785	)			(1,476	)			(5,144	)			(4,622	)
Provision for income taxes			511				9,603				7,355				2,588
Adjusted EBITDA		$	36,897			$	50,703			$	155,616			$	143,668

⁽¹⁾ _{Represents separation and related costs that were incurred subsequent to the separation on October 1, 2022, including expenses incurred on a transitional basis under a contract shared with Xperi Inc.}   

ADEIA INC. RECONCILIATION FOR GUIDANCE ON OPERATING EXPENSES (in millions) (unaudited)
		Year Ended
		December 31, 2026
		Low				High
GAAP operating expenses		$	283.0			$	289.0
Amortization expense			64.0				65.0
Stock-based compensation expense			34.0				35.0
Separation and related costs (1)			9.0				9.0
Total of non-GAAP adjustments			107.0				109.0
Non-GAAP operating expenses		$	176.0			$	180.0

⁽¹⁾ _{Represents separation and related costs that were incurred subsequent to the separation on October 1, 2022, including expenses incurred on a transitional basis under a contract shared with Xperi Inc.} 

ADEIA INC. RECONCILIATION FOR GUIDANCE ON NET INCOME (in millions) (unaudited)
		Year Ended
		December 31, 2026
		Low				High
GAAP net income		$	52.8			$	79.2
Amortization expense			64.0				65.0
Stock-based compensation expense			34.0				35.0
Separation and related costs (1)			9.0				9.0
Total of non-GAAP operating expenses			107.0				109.0
Non-GAAP tax adjustment (2)			(23.1	)			(23.9	)
Non-GAAP net income		$	136.7			$	164.3

⁽¹⁾ _{Represents separation and related costs that were incurred subsequent to the separation on October 1, 2022, including expenses incurred on a transitional basis under a contract shared with Xperi Inc.} 
⁽²⁾ _{The provision for income taxes is adjusted to reflect the net income tax effects of the various non-GAAP pretax adjustments.}

ADEIA INC. RECONCILIATION FOR GUIDANCE ON ADJUSTED EBITDA (in millions) (unaudited)
		Year Ended
		December 31, 2026
		Low				High
GAAP net income		$	52.8			$	79.2
Stock-based compensation expense			34.0				35.0
Separation and related costs (1)			9.0				9.0
Amortization expense			64.0				65.0
Depreciation expense			2.1				2.1
Interest expense			32.0				34.0
Other income			(6.0	)			(7.0	)
Income tax expense			13.2				19.8
Total of non-GAAP adjustments			148.3				157.9
Adjusted EBITDA		$	201.1			$	237.1

⁽¹⁾ _{Represents separation and related costs that were incurred subsequent to the separation on October 1, 2022, including expenses incurred on a transitional basis under a contract shared with Xperi Inc.}

• Q3 Revenue grew 151% year-over-year to $235 million
• Q3 Direct Channel Revenue grew 112% year-over-year to $119 million
• Q3 Third-Party Channel Revenue grew 209% year-over-year to $116 million

AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Ethos (Nasdaq: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced its financial results for the third quarter ended September 30, 2026.

“Q3 was a record quarter for Ethos. We grew revenue 151% year-over-year and delivered our third consecutive quarter of triple digit year-over-year growth,” said Peter Colis, CEO and Co-Founder of Ethos. “In Q3 alone, we protected more than 140,000 additional families. Our results illustrate the power of growth at scale paired with disciplined execution, and continue to show that Ethos is a business that gets better as it gets bigger.”

Third Quarter 2026 Financial Highlights

• Revenue: Grew 151% year-over-year to $235.2 million
• Direct Channel Revenue: Grew 112% year-over-year to $118.8 million
• Third-Party Channel Revenue: Grew 209% year-over-year to $116.4 million
• Gross Profit: $230.8 million, representing a 98% gross profit margin
• Contribution Profit: $66.4 million, a 28% contribution profit margin
• Net Income: $4.7 million, representing a 2% margin
• Net Income per Share: basic and diluted were $0.07 per share
• Non-GAAP Net Income: $33.8 million, representing a 14% margin
• Non-GAAP Net Income per Share: basic was $0.53 and diluted was $0.49 per share   
• Adjusted EBITDA: $34.9 million, representing a 15% margin
• Cash Flow: $40.7 million net cash provided by operations

Third Quarter 2026 Business Highlights

• Families Protected: Activated 142,111 new policies in Q3, representing 189% year-over-year growth
• Reported Average Revenue per Unit: $1,655, representing a 13% year-over-year decline due to a channel mix that skewed more heavily towards Ethos’ Third-Party channel.

Share Repurchase  

During the third quarter ended September 30, 2026, the Board of Directors of Ethos authorized a share repurchase program of up to $100 million of the Company’s outstanding Class A common stock. Since the announcement of such program no shares have been repurchased.

Financial Outlook  

For the fourth quarter of 2026, Ethos expects the following:

• Total Revenue: Between $220 million and $224 million, representing a 102% increase year-over-year at the midpoint
• Adjusted EBITDA: Between $30 million and $32 million

For the full fiscal year 2026, Ethos expects the following:

• Total Revenue: Between $838 million and $842 million, representing a 117% increase year-over-year at the midpoint
• Adjusted EBITDA: Between $134 million and $136 million

Ethos’ financial outlook for the fourth quarter and full fiscal year 2026 are forward-looking, and actual results may differ materially as a result of many factors. Refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause the company’s actual results to differ materially from these forward-looking statements.

Reconciliation of Adjusted EBITDA on a forward-looking basis to net income, the most directly comparable GAAP measure, is not available without unreasonable efforts due to high variability and complexity and low visibility with respect to certain charges excluded from this non-GAAP measure, including interest expense, interest income, and income tax expenses. Ethos expects the variability of these items could have a significant, and potentially unpredictable, impact on its future GAAP financial results.

Conference Call Information

Ethos will host a conference call for analysts and investors to discuss its earnings results for the third quarter 2026 and outlook for its fourth fiscal quarter and fiscal year 2026 today at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). A live webcast and accompanying presentation can be accessed through the events section of the Ethos investor relations website at investors.ethos.com. A recorded webcast of the event will also be available on the Ethos Investor Relations website.    

Non-GAAP Financial Information

Ethos has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). We believe that non-GAAP financial measures, among others, provide important supplemental information to management and investors, help evaluate our business, identify trends affecting our performance, formulate business plans, and make strategic decisions.

The presentation of these non-GAAP financial measures is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the financial tables below.

Adjusted EBITDA –  Ethos defines Adjusted EBITDA as net income excluding interest expense, interest income, income tax expense (benefit), depreciation and amortization, and stock-based compensation expense and related taxes as set forth in the table below. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA for a period by revenue for the same period. Ethos uses Adjusted EBITDA and Adjusted EBITDA Margin to assess performance, to inform the preparation of its annual operating budget and quarterly forecasts, to evaluate the effectiveness of its business strategies, and to assist its board of directors in monitoring its business and financial performance. Ethos believes that Adjusted EBITDA and Adjusted EBITDA Margin provide useful information to investors about its business and financial performance, enhance their overall understanding of its past performance and future prospects, including by providing consistency and comparability with its past financial performance, and allow for greater transparency with respect to measures used by its management in investors’ financial and operational decision making. In addition, Ethos believes Adjusted EBITDA is widely used by investors, securities analysts, and other parties in evaluating companies in its industry as a measure of operational performance.

Contribution Profit – Ethos defines Contribution Profit as gross profit less sales and marketing expense, which includes agent payments and underwriting costs for non-activated policies, plus stock-based compensation and related taxes related to its employees and overhead costs allocated to sales and marketing expenses. Gross profit is defined as revenue less cost of revenue. Cost of revenue primarily consists of underwriting costs associated with activated policies. Overhead costs allocated to sales and marketing expenses include professional fees, technology expenses, and other related expenses. Contribution Margin is calculated by dividing Contribution Profit for a period by revenue for the same period.

Non-GAAP Net Income and Non-GAAP Net Income Per Share, Basic and Diluted – Ethos defines non-GAAP net income as net income/(loss), adjusted to exclude stock-based compensation and related taxes, to provide investors and management with greater visibility into the underlying performance of its recurring core business operations. Ethos defines non-GAAP net income per share, basic, as non-GAAP net income divided by the weighted-average shares outstanding. Ethos defines non-GAAP net income per share, diluted, as non-GAAP net income divided by the weighted-average shares outstanding, which includes the dilutive effect of potentially diluted common stock equivalents outstanding during the period, if any.

About Ethos

Ethos is a leading life insurance technology company on a mission to protect families by democratizing access to life insurance and empowering agents at scale. With its robust three-sided technology platform, Ethos is transforming the life insurance experience for consumers, agents, and carriers alike. Ethos offers instant, accessible products and a seamless online process that requires no medical exams and just a few health questions; it eliminates traditional barriers, making it easier than ever for everyone to protect their families. Ethos is redefining how life insurance is bought, sold, and underwritten.

Learn more at ethos.com.

Investor Relations Contact:
Aaron Turner
ir@ethos.com

Press Contact:
Allyson Savage
press@ethos.com

Forward-Looking Statements

This press release and the related conference call contain express and implied “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding potential share repurchases, Ethos’ financial outlook for the fiscal quarter ending December 31, 2026 and the fiscal year ending December 31, 2026, the size of Ethos’ market opportunity, market trends, and Ethos’ business and financial strategy and plans. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” or similar expressions. Such statements are subject to risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. These include, but are not limited to: Ethos’ limited operating history at its current scale, scope and complexity; the growth rate of the markets in which Ethos competes; Ethos’ ability to effectively manage and sustain its growth; Ethos’ ability to compete with existing competitors and new market entrants; Ethos’ ability to attract new and retain existing carriers and agency counterparties; adoption of and engagement with Ethos’ platform by individual agents; Ethos’ brand awareness and the success of its marketing efforts to grow its business; potential damage to Ethos’ reputation; disruptions or other business interruptions that affect the availability of Ethos’ platform. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements contained herein are included in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Ethos’ most recent filings with the Securities and Exchange Commission, including in its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026.  Except as required by law, Ethos undertakes no obligation, and does not intend, to update these forward-looking statements.

ETHOS TECHNOLOGIES INC. Condensed Consolidated Statements of Operations (In Thousands, Except Per Share Data) (Unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue:
Commission		$	235,215			$	93,794			$	617,876			$	277,531
Total revenue			235,215				93,794				617,876				277,531
Costs and expenses:
Sales and marketing			169,423				57,074				441,616				165,205
General and administrative			39,176				8,871				243,730				30,414
Technology (exclusive of amortization)			16,480				7,769				57,414				24,711
Cost of revenue			4,451				1,677				11,707				4,674
Depreciation and amortization			1,838				1,332				4,757				4,075
Total costs and expenses			231,368				76,723				759,224				229,079
Income (loss) from operations			3,847				17,071				(141,348	)			48,452
Other income (expense):
Interest expense			(358	)			(786	)			(1,636	)			(2,405	)
Interest income			1,908				1,410				5,050				4,472
Other income, net			65				42				170				100
Total other income, net			1,615				666				3,584				2,167
Net income (loss) before income tax expense			5,462				17,737				(137,764	)			50,619
Income tax expense			790				1,863				4,424				4,029
Net income (loss)			4,672				15,874				(142,188	)			46,590
Deemed dividend on the conversion of Series D and D-1 redeemable convertible preferred stock			—				—				(5,642	)			—
Net income (loss) attributable to common stockholders		$	4,672			$	15,874			$	(147,830	)		$	46,590
Per share data:
Basic net income (loss) per share		$	0.07			$	0.96			$	(2.52	)		$	2.83
Diluted net income (loss) per share		$	0.07			$	0.27			$	(2.52	)		$	0.80
Weighted-average shares used in computing basic net income (loss) per share			64,396				16,556				58,669				16,453
Weighted-average shares used in computing diluted net income (loss) per share			69,207				58,222				58,669				58,593

ETHOS TECHNOLOGIES INC. Condensed Consolidated Balance Sheets (In Thousands) (Unaudited)
		September 30,				December 31,
		2026				2025
Assets
Current assets:
Cash and cash equivalents		$	149,800			$	91,091
Short-term investments			71,656				34,876
Accounts receivable, net			83,464				36,498
Commissions receivable-current, net			33,936				28,786
Prepaid and other current assets			68,752				54,553
Total current assets			407,608				245,804
Long-term assets:
Commissions receivable, net			315,389				224,219
Property and equipment, net			12,097				8,189
Operating lease right-of-use assets			1,354				2,183
Goodwill			2,238				2,238
Acquired intangible assets, net of amortization			587				662
Long-term investments			68,613				31,468
Other long-term assets			633				574
Total long-term assets			400,911				269,533
Total assets		$	808,519			$	515,337
Liabilities, redeemable preferred stock and stockholders’ equity
Current liabilities:
Accounts payable		$	77,558			$	55,070
Accrued expenses			109,384				39,224
Liabilities related to sale of commissions receivable, current			8,314				11,750
Operating lease liabilities, current			875				1,125
Other current liabilities			80,692				6,021
Total current liabilities			276,823				113,190
Long-term liabilities:
Liabilities related to sale of commissions receivable, non-current			7,061				12,509
Operating lease liabilities, non-current			619				1,228
Deferred tax liability			11,867				8,529
Total long-term liabilities			19,547				22,266
Total liabilities			296,370				135,456
Commitments and contingencies
Redeemable convertible preferred stock, par value $0.0001			—				403,997
Stockholders’ deficit:
Common stock, $0.0001 par value			6				2
Additional paid-in capital			759,000				78,950
Accumulated other comprehensive loss			(2,155	)			(554	)
Accumulated deficit			(244,702	)			(102,514	)
Total stockholders’ equity (deficit)			512,149				(24,116	)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity		$	808,519			$	515,337

ETHOS TECHNOLOGIES INC. Condensed Consolidated Statements of Cash Flows (In Thousands) (Unaudited)
		Nine Months Ended September 30,
		2026				2025
Cash flows from operating activities
Net income (loss)		$	(142,188	)		$	46,590
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred taxes			3,338				3,483
Depreciation and amortization			4,757				4,075
Non-cash interest expense			1,636				2,405
Amortization of discounts and premium, investments			(962	)			(994	)
Stock-based compensation expense			237,296				10,564
Operating lease right-of-use asset amortization			828				635
Unrealized foreign currency translation			(205	)			(244	)
Changes in operating assets and liabilities:
Prepaid and other assets			(21,183	)			(15,889	)
Accounts payable			22,641				35,266
Accounts receivable			(46,966	)			(5,636	)
Commissions receivable			(5,150	)			(11,014	)
Long-term commissions receivable			(91,170	)			(35,507	)
Accrued expenses			71,119				10,517
Other current liabilities			73,813				(12,220	)
Other long-term liabilities			—				(750	)
Net cash provided by operating activities			107,604				31,281
Cash flows from investing activities
Purchase of property and equipment			(1,350	)			(1,101	)
Purchase of investments			(145,532	)			(52,509	)
Proceeds from maturity of investments			70,615				79,870
Investment in software development costs			(5,328	)			(3,145	)
Net cash provided by (used in) investing activities			(81,595	)			23,115
Cash flows from financing activities
Proceeds from issuance of Class A common stock in initial public offering, net of underwriting discounts and commissions			91,580				—
Proceeds from liabilities related to sale of commissions receivable			—				5,000
Taxes paid related to net share settlement of restricted stock units			(49,085	)			—
Repayment of liabilities related to sale of commissions receivable			(10,196	)			(7,802	)
Proceeds from equity incentive plans and warrant exercise			3,352				794
Payment of deferred offering costs			(2,843	)			(3,175	)
Net cash provided by (used in) financing activities			32,808				(5,183	)
Net increase in cash and cash equivalents			58,817				49,213
Effect of exchange rates on cash			(108	)			(19	)
Cash and cash equivalents, beginning of period			91,091				35,075
Cash and cash equivalents, end of period		$	149,800			$	84,269

ETHOS TECHNOLOGIES INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (In Thousands) (Unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
		(in thousands)
Gross profit		$	230,764			$	92,117			$	606,169			$	272,857
Less: sales and marketing			(169,423	)			(57,074	)			(441,616	)			(165,205	)
Add: stock-based compensation and related taxes allocated to sales and marketing			(170	)			23				11,413				2,043
Add: professional fees allocated to sales and marketing			1,806				258				3,156				1,174
Add: technology expenses allocated to sales and marketing			2,137				750				4,823				2,197
Add: other expenses allocated to sales and marketing			1,310				620				3,392				1,746
Contribution profit		$	66,424			$	36,694			$	187,337			$	114,812
Gross profit margin			98	%			98	%			98	%			98	%
Contribution profit margin			28	%			39	%			30	%			41	%

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
		(in thousands)
Net income (loss)		$	4,672			$	15,874			$	(142,188	)		$	46,590
Stock-based compensation and related taxes			29,170				272				240,163				10,564
Non-GAAP net income		$	33,842			$	16,146			$	97,975			$	57,154
Interest expense			358				786				1,636				2,405
Interest income			(1,908	)			(1,410	)			(5,050	)			(4,472	)
Income tax expense			790				1,863				4,424				4,029
Depreciation and amortization			1,838				1,332				4,757				4,075
Adjusted EBITDA		$	34,920			$	18,717			$	103,742			$	63,191
Net income (loss) margin			2	%			17	%			-23	%			17	%
Non-GAAP net income margin			14	%			17	%			16	%			21	%
Adjusted EBITDA margin			15	%			20	%			17	%			23	%

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
		(in thousands)
Stock–based compensation and related taxes
Sales and marketing		$	(170	)		$	23			$	11,413			$	2,043
General and administrative			25,603				137				205,538				5,905
Technology (exclusive of amortization)			3,737				112				23,212				2,616
Total		$	29,170			$	272			$	240,163			$	10,564

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
		(in thousands, except per share data)
GAAP net income (loss)		$	4,672			$	15,874			$	(142,188	)		$	46,590
Deemed dividend on the conversion of Series D and D-1 redeemable convertible preferred stock			—				—				(5,642	)			—
GAAP net income (loss) attributable to common stockholders		$	4,672			$	15,874			$	(147,830	)		$	46,590
GAAP net income (loss)		$	4,672			$	15,874			$	(142,188	)		$	46,590
Add back: Stock-based compensation expense and related taxes			29,170				272				240,163				10,564
Non-GAAP net income		$	33,842			$	16,146			$	97,975			$	57,154
Deemed dividend on the conversion of Series D and D-1 redeemable convertible preferred stock			—				—				(5,642	)			—
Non-GAAP net income attributable to common stockholders		$	33,842			$	16,146			$	92,333			$	57,154
Per share data:
Weighted-average shares used in computing GAAP net income (loss) per share, basic			64,396				16,556				58,669				16,453
Weighted-average shares used in computing GAAP net income (loss) per share, diluted			69,207				58,222				58,669				58,593
Weighted-average shares used in computing non-GAAP net income per share, basic			64,396				16,556				58,669				16,453
Weighted-average shares used in computing non-GAAP net income per share, diluted			69,207				58,222				65,707				58,593
GAAP net income (loss) per share attributable to common stockholders, basic		$	0.07			$	0.96			$	(2.52	)		$	2.83
GAAP net income (loss) per share attributable to common stockholders, diluted		$	0.07			$	0.27			$	(2.52	)		$	0.80
Non-GAAP net income per share attributable to common stockholders, basic		$	0.53			$	0.98			$	1.57			$	3.47
Non-GAAP net income per share attributable to common stockholders, diluted		$	0.49			$	0.28			$	1.41			$	0.98

Conference call and webcast to be held at 4:30 p.m. ET

NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio^™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the quarter ended September 30, 2026. 

Conference Call and Webcast
To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company’s website following the event.

About Trevi Therapeutics, Inc.       
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio^™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.   

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients’ quality of life.       
    
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially. 

The FDA has conditionally accepted Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact     
Jonathan Carlson     
Trevi Therapeutics, Inc.     
(203) 654 3286     
IR@trevitx.com  
  
Media Contact     
Rosalia Scampoli     
914-815-1465     
rscampoli@marketcompr.com     

TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

• 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT (9:00 a.m. ET) on Tuesday, November 17, 2026
• 9^th Annual Evercore Healthcare Conference at 1:45 p.m. ET on Tuesday, December 1, 2026
• Citi’s 2026 Global Healthcare Conference at 9:40 a.m. ET on Wednesday, December 2, 2026

The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company’s website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com        

HIGHLIGHTS 

Exploration drill program in Q4 2026 is focused on Tibooburra Gold Project, New South Wales.

• Novo will commence a ~2,700 m RC program at Tibooburra, NSW, with drilling at the Clone prospect anticipated to commence in early-November 2026.
• Surface geochemical sampling including regional streams, targeted soils and rock chips; along with geological mapping was completed in Q3 2026. Assays are pending for the collected samples.

Egina and Farno Projects

• Novo is undertaking a comprehensive review of all geological data relating to the Egina Gold Project, with the review aiming to identify targets for drilling programs at Egina in H1 2027, subject to all approvals being obtained.
• Under the Farno JV with Northern Star Resources (NST), NST has been completing mapping, rock chip sampling, interpretation and soils resampling of historic AC holes. This is to develop a more holistic interpretation over the JV tenement.
• Drill planning is now underway for a maiden RC drilling program at the Teichman Gold Project in Q1 2027.   This program has been delayed due to on-going work to secure all regulatory and heritage access approvals.
• Further soil sampling has been completed at the Teichman and follow up programs ongoing at the Egina project with results pending.

Onslow District, Western Australia

• Novo are awaiting grant of tenement applications with planning underway for on-ground mapping and sampling reconnaissance programs as well as ground gravity and passive seismic geophysical surveys over the identified targets.

Wyloo Project, Western Australia

• Follow up reconnaissance mapping and infill soil sampling occurred at the Vera and Kavira prospects in Q3 2026 with samples being analysed using the Ultrafine+™ analytical method. Follow up drilling is planned for 2027, subject to heritage approvals being obtained.

Belltopper Gold Project (Victoria) being advanced

• Novo is considering all strategic options including securing a project partners for the potential advancement of the Belltopper Gold Project in Victoria.

Corporate

• Increase in the value of Novo’s investment in San Cristobal Mining Inc takes the value of the investment to A$36.2 million (C$35.9 million)
• In line with the Joint Venture and Option agreement between Novo, Manhattan Gold Corporation Ltd and Awati Resources Pty Ltd (Awati) – a fully owned subsidiary of Manhattan Gold, Novo issued 1,500,000 common shares at the value of A$100k (C$99k) to Awati on 31 July 2026.
• Cash balance of A$8.5 million (C$8.3 million) and investments of approximately A$38.1 million (C$37.7 million) as at 30 September 2026.

Novo Field Assistant conducting reconnaissance rock chip sampling at the Vera prospect at the Wyloo Polymetallic Project, Pilbara Region Western Australia.

PERTH, Australia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to report on the recent and planned key activities of the Company.

PORTFOLIO

Novo continues to assemble a diversified gold exploration and development portfolio located across leading mining provinces in Australia, comprising a mix of greenfields, advanced greenfields, and advanced exploration projects.

A dedicated project generation program continues to focus on identifying advanced gold and copper assets to further enhance Novo’s portfolio.

WESTERN AUSTRALIAN PORTFOLIO

Exploration programs completed across the Company’s Pilbara project portfolio (Figure 1) have provided several high-priority drill targets where RC drilling is planned for 2027, subject to grant of tenements and land access approvals.

Figure 1: Novo Pilbara and Onslow tenure showing main projects and significant prospects.

Wyloo Polymetallic Project

In Q2 2026, soil sampling and rock chip samples were collected to the southeast of the Wyloo SE prospect. A total of 142 minus 80 mesh soil samples were collected at a 80 m x 20 m spacing highlighting the 600 m long, 270 m wide Vera antimony – arsenic soil anomaly which is open to the north and east (Figure 2).

Figure 2. Stream sediment and rock Sb assay results over geology, showing the Kavira and Vera prospects to the west and east of Wyloo SE

The field team has recently completed follow up on-ground soil sampling at the Vera and Kavira prospects, located to the east and west (respectively) of Wyloo SE (Figure 2). This fieldwork has been focussed on defining the extent of the mineralised system across the southern portion of the Wyloo E47/4213 tenement. Ongoing work over the Kavira stream sediment anomaly was completed in Q3 2026. This infill soil sampling is being analysed using the Ultrafine+™, an analytical technique designed to detect anomalism beneath Tertiary transported cover, with results still pending.

Fieldwork at the Vera and Kavira prospects is progressing in preparation for an AC drilling program planned for 2027, designed to drill under the Tertiary transported cover, subject to the receipt of land access approvals including heritage surveys.

Egina Gold Camp

As previously advised by Novo on 27 May 2026 (refer to Novo’s ASX announcement entitled “Egina Gold Project Update”), Northern Star Resources Ltd (ASX:NST) (NST) informed Novo that they are withdrawing from the earn-in under the Egina Earn In and Joint Venture Agreement.

The data from Northern Star’s recent exploration activities is being reviewed and soil sampling within the Egina Gold Project tenements is ongoing in November 2026. Novo has engaged Consultant Geologist Allan Kneeshaw, who was involved with the discovery of the Hemi Gold Project, to review the litho-geochemistry of the Egina Gold Project and assist Novo’s geological team in identifying gold mineralisation targets adjacent to the Millindinna Intrusive Suite in preparation for drilling programs in 2027. An update on the results of this review is planned for release in December 2026.

The Millindinna Intrusive Suite is an Archean layered mafic – ultramafic intrusive suite which has intruded older sedimentary sequences in the Mallina Basin. The Suite is closely associated with regional exploration targets, including intrusive gold systems (such as Hemi-style targets).

Figure 3 – Egina Gold Project and Egina Gold Camp Tenements.

Target areas along structural corridors related to the suite are considered highly prospective for Hemi style gold mineralisation and will be the focus of the Novo geological team’s exploration field work in the Pilbara Craton’s Central Pilbara Tectonic Zone.

Farno Joint Venture

Under the Farno JV with Northern Star Resources (NST), NST has been completing mapping, rock chip sampling, interpretation and spoils resampling of historic AC holes. This is to develop a more holistic interpretation over the JV tenement.

NST proposes on-ground gravity and Induced Polarisation (IP) geophysical surveys of the Farno JV tenement, E47/2502, subject to land access approvals. The geophysical surveys are designed to develop targets for potential drill testing.

However, due to heritage constraints exploration has been limited to low impact activities in areas which can be accessed.

Teichman Gold Project

Novo is also advancing gold exploration at the Teichman Gold Project, which is part of the Croydon JV (70% Novo and 30% Runnel Holdings Pty Ltd, an entity of Mark Gareth Creasy (Creasy Group)).

The project area includes multiple historic workings centred on two main mineralised shear zones, over an area of approximately 2.5 km by 1.3 km. Previous exploration at Teichman included mapping and surface sampling and has defined multiple shear-hosted gold targets along the Pride and Teichman trends (Figure 4).

On ground fieldwork undertaken this month consisted of gridded soil sampling designed to further define targets for a maiden RC drilling program. Results from this sampling are still pending. This program followed discussions with the Mugarinya Community, which facilitated Novo’s access to the Yandeyarra Reserve to undertake low-impact exploration.

Heritage surveys are planned to clear a program of RC drilling for H1 2027 following delays in heritage access agreements being finalised.

Figure 4 – Teichman prospects highlighting Novo rock chip results > 5 g/t Au and geological interpretation with regolith cover.¹

BELLTOPPER GOLD PROJECT – VICTORIA

Internal mining studies completed based on the updated Exploration Target announced in February 2026, that assumed underground mining and toll treatment, support the current evaluation of development options for the Belltopper Gold Project in Victoria.

Novo is considering all strategic options including securing a project partner for the potential development of the project.  Recent mining approvals within Victoria, including the exploration tunnel at Southern Cross Gold’s Sunday Creek Project, provides confidence that the regulatory environment within Victoria can support further consideration of an appropriately assessed and studied underground gold project at Belltopper.

Work continues to define the potential of Belltopper. The selection of preliminary drill site location selection has commenced for potential drilling in H1 2027, aiming to provide further confidence in the updated 2026 Exploration Target (Figure 5) and the definition of further potential reefs.

A program of 2,500 m of diamond drilling will target a number of known and expected reefs in the core central portion of the Exploration Target, focussed at the Belltopper anticline and converging reefs in the nose of the structure.

Figure 5 – Overview Map of the Belltopper Gold Project showing location of the eight reefs included in the 2026 Exploration Target, downhole gold tenor, historical workings, and important geological elements of the field.

TIBOOBURRA GOLD PROJECT – NEW SOUTH WALES

Figure 6 – Location map showing Novo’s Tibooburra, NSW project

A ~2,700 m Reverse Circulation (RC) drilling program is scheduled to commence at the Tibooburra Gold Project (Tibooburra) (Figure 6) in Q4 2026, as Novo has now obtained all required regulatory and land holder approvals. RC drilling is planned to test the Clone prospect (~2,700 m) and follow up the results of the 2025 drilling program that identified plunging high-grade shoots that are open in multiple directions.

Figure 7 – Location, tenure and key prospects at Tibooburra, NSW. Tenements EL9867 and EL9900 are newly granted (and 100% owned by Novo). All other tenements belong to the Tibooburra Gold Project Farm-In JV with Awati Resources Pty Ltd (wholly owned subsidiary of Manhattan Gold Corporation Ltd).

Regional stream sediment sampling, coupled with targeted mapping and gridded surface soil sampling, commenced in September and a follow up sampling program is underway. This fieldwork aims to generate new gold-anomalous zones in potentially recessive areas on the 30 km long Albert Goldfield, grow the target pipeline, and help prioritise those targets for potential future exploration drilling in H1 2027.

SUSTAINABILITY

There were no safety, environmental or heritage incidents reported during Q3.

Discussions with representatives of various Traditional Owners are ongoing as Novo reviews and updates the relevant access agreements. Novo continues to work closely with the Mugarinya Community Board, whose approval is required to allow exploration drilling to take place within the Yandeyarra Reserve once Western Australian Government approval has also been received. Novo remains in close contact with Traditional Owners to ensure appropriate heritage protection for planned exploration activities across all of its projects.

CORPORATE

Project Generation

Novo continues to focus its efforts on a dedicated and disciplined project generation program to identify value accretive opportunities across targeted gold and copper assets that complement the Company’s current portfolio. The Company is currently working on potential opportunities with third parties, none of which are sufficiently advanced to warrant disclosure, and the Company will make an announcement if and when any of these opportunities become formal and binding.

Comet Well and Purdy’s North

As announced in February 2025, Novo’s board of directors resolved to seek interest from parties to acquire or be part of a joint venture in relation to the Comet Well and Purdy’s North project. This process remains on-going. As part of this decision, a sale process for the Mechanical Ore Sorter is underway.

Relinquishment of Tenure

The Company’s exploration programs across key Pilbara areas continue to successfully identify priority targets for follow-up drilling, while also identifying tenure that provides little further exploration value.

As a result, tenure which does not complement Novo’s exploration strategy continues to be relinquished to reduce land tenure holding costs.

The Company currently manages an estimated ~5,620 sq km of 100% owned tenure, of which ~626 sq km of tenure forms the Harding Dam Battery Metal Joint Venture (SQM Priority tenements), both managed by our JV partners. Novo has reduced annual holding costs by entering into joint ventures, or by relinquishing or divesting tenure of limited prospectivity.

Financial Update

As of 30 September 2026, Novo had a cash balance of A$8.5 million (C$8.3 million).

In addition, Novo has an investment portfolio of shares held in ASX-listed and unlisted companies that is valued at approximately A$38.1 million (C$37.7 million), consisting of:

(1) ASX-listed companies, valued at approximately A$1.5 million (C$1.5 million) based on the closing price of those shares on 30 September 2026; and

(2) Unlisted companies, valued at approximately A$36.6 million (C$36.3 million) as of 30 September 2026.

	Ticker	Number of shares held	Novo’s interest	Value A$’000		Value C$’000
(1) ASX-listed shares
Kalamazoo Resources Limited	ASX: KZR	10,000,000	2.63%	$1,450		$1,437
Kali Metals Limited (commenced trading 8 January 2024)	ASX: KM1	566,947	0.28%	$52		$52
(2) Unlisted shares*
Elementum 3D Inc. (E3D)	N/A	2,076,560	8.63%	$416		$412
San Cristobal Mining Inc. (SCM)	N/A	1,242,500	2.39%	$36,193		$35,860

* The investment portfolio values shown are in line with management’s valuation as at 30 September 2026.

Share Registry

A snapshot of Novo’s top 10 shareholders as at 30 September 2026 is set out below for reference*.

*Please note that the above list of shareholders excludes the objecting beneficial owners and non-objecting beneficial owners as defined in National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer published by the Canadian Securities Administrators, and these shareholders with holdings above 1% hold approximately 8% of the register.

Authorised for release by Board of Directors.

CONTACT

Investors: Mike Spreadborough +61 8 6400 6100 info@novoresources.com

North American Queries: Leo Karabelas. +1 416 543 3120 leo@novoresources.com

Media: Peter Tayler. +61 412 036 231 peter@nwrcommunication.com.au

QP STATEMENT

Mr Rohan Williams (MAusIMM), is the qualified person, as defined under National Instrument 43-101 Standards of Disclosure for Mineral Projects, responsible for, and having reviewed and approved, the technical information contained in this news release, as well as having verified the data disclosed, including sampling, analytical and test data underlying the information or opinions contained in the written disclosure. Mr Williams is the General Manager, Exploration at Novo.

Dr Christopher Doyle (MAIG) and Dr Simon Dominy (FAusIMM CPGeo; FAIG RPGeo), are the qualified persons, as defined under National Instrument 43-101 Standards of Disclosure for Mineral Projects, responsible for, and having reviewed and approved, the technical information contained in this news release that relates to the Belltopper Exploration Target. Dr Doyle is Novo’s Exploration Manager – Victoria and Dr Dominy is a Technical Advisor to Novo.

JORC COMPLIANCE STATEMENTS

Previous Exploration Results

The information in this news release that relates to Exploration Results from Novo’s Teichman Project is extracted from Novo’s ASX announcement entitled “Strong Gold Results from Teichman; High-Grade Antimony Results from Sherlock” dated 11 November 2025, and is available to view at www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the information included in the original market announcement and that all material assumptions and technical parameters underpinning the estimates in the market announcement continue to apply and have not materially changed. The Company confirms that the form and context in which the Competent Person’s findings are presented have not been materially modified from the original market announcement.

Belltopper Exploration Target

Novo initially announced its updated 2026 Exploration Target for Belltopper to ASX on 11 February 2026 in its announcement entitled “Novo Delivers Significant Increase to Belltopper Exploration Target” (which is available to view at www.asx.com.au) (Exploration Target Announcement).

The information in this announcement that relates to the Belltopper Exploration Target is based on information compiled by:

(a) Dr Christopher Doyle, a Competent Person who is a Member of the Australasian Institute of Geoscientists (MAIG). Dr Doyle is Exploration Manager – Victoria for Novo and is a full-time employee of Novo. Dr Doyle has sufficient experience that is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves”. Dr Doyle consents to the inclusion in this announcement of the matters based on his information in the form and context in which it appears; and

(b) Dr Simon Dominy, a Competent Person who is a Fellow of both the Australasian Institute of Geoscientists (FAIG RPGeo) and the Australasian Institute of Mining and Metallurgy (FAusIMM CPGeo). Dr Dominy is a Technical Advisor contracted to Novo. Dr Dominy has sufficient experience that is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves”. Dr Dominy consents to the inclusion in this announcement of the matters based on his information in the form and context in which it appears.

As a basis for the Belltopper Exploration Target, Novo applied its geological understanding of the reef network at Belltopper, drawing upon 3D reconstruction of historic mining and exploration data, drilling data, structural and geochemical data, field mapping (including high-resolution LiDAR™ interpretation), and surface rock chip sampling. Further information about Novo’s Exploration Target at Belltopper, along with a more detailed explanation of the basis for the Exploration Target (including a specific description of the level of exploration activity already completed at Belltopper), is contained in the Exploration Target Announcement.

DISCLAIMER

This Business Review constitutes a voluntary disclosure by the Company and is not a Quarterly Activities Report for the purposes of ASX Listing Rules 5.3 and 5.5 for which Novo has an exemption, as a foreign entity with its primary listing on an overseas exchange with a particular obligation imposed by the home exchange that is comparable to the ASX Listing Rule obligation.

FORWARD-LOOKING INFORMATION

Some statements in this news release may contain “forward-looking statements” within the meaning of Canadian and Australian securities law and regulations. In this news release, such statements include but are not limited to planned exploration activities and the timing of such. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, without limitation, customary risks of the resource industry and the risk factors identified in Novo’s annual information form for the year ended December 31, 2025 (which is available under Novo’s profile on SEDAR+ at www.sedarplus.ca and at www.asx.com.au), and in the Company’s options prospectus dated 9 March 2026 and in the Company’s prospectus dated 2 August 2023, both of which are available at www.asx.com.au. Forward-looking statements speak only as of the date those statements are made. Except as required by applicable law, Novo assumes no obligation to update or to publicly announce the results of any change to any forward-looking statement contained or incorporated by reference herein to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements. If Novo updates any forward-looking statement(s), no inference should be drawn that the Company will make additional updates with respect to those or other forward-looking statements.

ABOUT NOVO

Novo is an Australian based gold explorer listed on the ASX and the TSX focussed on discovering standalone gold and copper projects with > 1 Moz Aueq development potential. Novo is an innovative gold explorer with a significant land package covering approximately 5,608 square kilometres in the Pilbara region of Western Australia, along with the 22 square kilometre Belltopper project in the Bendigo Tectonic Zone of Victoria, Australia. In addition to the above, Novo is part of a farm in agreement in New South Wales.

Novo has a significant investment portfolio and a disciplined program in place to identify value accretive opportunities that will build further value for shareholders.

Please refer to Novo’s website for further information including the latest corporate presentation.

#Refer to De Grey’s ASX Announcement, Hemi Gold Project mineral Resource Estimate (MRE) 2024, dated 14 November 2024. No assurance can be given that a similar (or any) commercially viable mineral deposit will be determined at Novo’s Becher Project.

_________________________________
¹ Refer to Novo’s ASX announcement dated 11 November 2025/news release disseminated in North America on November 11. 2025 – Strong Gold Results from Teichman; High-Grade Antimony Results from Sherlock

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/56b5903d-f54f-4406-bbe8-5ba7149e01da

https://www.globenewswire.com/NewsRoom/AttachmentNg/e65122b0-4236-4f03-96cb-5af71cd80f04

https://www.globenewswire.com/NewsRoom/AttachmentNg/0ba6f52e-5bf4-4bd4-94de-e1e8c652db9f

https://www.globenewswire.com/NewsRoom/AttachmentNg/cfc22e9a-4d1d-4926-b76b-2ac1785769b4

https://www.globenewswire.com/NewsRoom/AttachmentNg/0d8d40d4-3ca6-4bac-a39d-2d92ddc0d090

https://www.globenewswire.com/NewsRoom/AttachmentNg/dbd4273b-0a35-4b6d-9d04-6b744ad31228

https://www.globenewswire.com/NewsRoom/AttachmentNg/f4327621-1529-46ef-8538-5f0ada1fba1f

https://www.globenewswire.com/NewsRoom/AttachmentNg/f511053c-d7d7-4407-8972-06a21571462d

https://www.globenewswire.com/NewsRoom/AttachmentNg/ed83354d-d977-4f51-8cd3-e50e4b42fe46

https://www.globenewswire.com/NewsRoom/AttachmentNg/d1853d6c-510d-4807-9377-a34dfb0bb2ec

https://www.globenewswire.com/NewsRoom/AttachmentNg/c54f5c88-a5e7-4b00-befd-2fd4db717208

The fragrance icon inspires two new scents, A Thousand Wishes Granted and A Thousand Crystal Wishes, a new solid perfume format and a holiday campaign featuring global fashion icon Valentina Ferrer

What you should know:

• Bath & Body Works is celebrating A Thousand Wishes, one of its most-loved fragrance icons, with two new interpretations of the original scent: A Thousand Wishes Granted and A Thousand Crystal Wishes
• The collection introduces a new solid perfume format for A Thousand Wishes and A Thousand Wishes Granted, offering consumers another way to wear and layer the fragrances.
• A Thousand Crystal Wishes introduces a collectible new eau de parfum, embellished with crystals by Swarovski. Just 1,000 individually numbered bottles were created, a nod to the fragrance’s thousand wishes inspiration, and will be available through Bath & Body Works Drops on November 11 and at select stores while supplies last.
• Global fashion icon and A Thousand Wishes muse Valentina Ferrer brings the fragrance’s signature spirit to a wider international audience and a new generation of consumers.
• The launch brings Bath & Body Works’ Consumer First Formula to one of its biggest fragrance icons, pairing product upgrades and a holiday campaign with wider access through Ulta Beauty, Amazon and Drops.

COLUMBUS, Ohio, Nov. 02, 2026 (GLOBE NEWSWIRE) — This holiday, Bath & Body Works is celebrating the iconic fragrance A Thousand Wishes with the introduction of two new interpretations of the original: A Thousand Wishes Granted and A Thousand Crystal Wishes. New solid perfume formats offer another way to wear both A Thousand Wishes and A Thousand Wishes Granted, while A Thousand Crystal Wishes completes the collection with a collectible eau de parfum embellished with crystals by Swarovski. The launch comes to life through a holiday campaign featuring global fashion icon and A Thousand Wishes muse Valentina Ferrer.

The Original Favorite, A Thousand Wishes

Since its launch in 2014, A Thousand Wishes has become one of Bath & Body Works’ most enduring fragrance icons. Featuring notes of pink prosecco, sparkling quince, crystal peonies, gilded amber and amaretto crème, the fragrance is known for its sparkling character and association with celebration, making it a favorite for both gifting and everyday wear.

More than 10 years later, A Thousand Wishes continues to rank among Bath & Body Works’ most-loved fragrances. The fragrance has generated over $1 billion in total sales since launch and ranked among the brand’s top five fragrances by total shop sales in 2025.

The expansion reflects Bath & Body Works’ Consumer First Formula, including product innovation through new formats, enhanced fragrance quality through higher fragrance concentrations and expanded access through Bath & Body Works stores, Ulta Beauty and Amazon. Together, these enhancements give consumers more ways to discover, wear, and enjoy one of the brand’s most loved fragrance icons.

“A Thousand Wishes has become a Bath & Body Works icon because of its ability to evoke joy, celebration and emotional connection through fragrance,” said Mary Testa-Gough, assistant vice president of product & fragrance development at Bath & Body Works. “As we continue to invest in our most loved fragrances, we remain focused on elevating every touchpoint of the scent experience through enhanced fragrance quality, improved longevity, and innovative formats that enable consumers to build a fragrance wardrobe for every mood, moment, and ritual.”

Meet A Thousand Wishes Granted

The collection expands this season with the introduction of A Thousand Wishes Granted, a fragrance that builds on the spirit of the original while offering a new scent experience. The fragrance combines bright fruit notes of wild raspberry accord and fresh bergamot with warm, soft marshmallow musk and golden amber for a more intimate expression of the original.

Consumers will also find new ways to enjoy the collection with the introduction of solid perfume for both A Thousand Wishes and A Thousand Wishes Granted. The portable format offers a convenient way to refresh and layer the fragrances throughout the day, while the dermatologist-approved* formula glides onto skin with a lightweight feel.

The collection also features enhancements across select fragrance and body care products, including higher fragrance concentrations in fine fragrance mist and eau de parfum for longer-lasting wear, along with refreshed packaging.

Embellished with Swarovski® Crystals: A Thousand Crystal Wishes

A Thousand Crystal Wishes brings the most elevated expression to the collection, featuring notes of sparkling raspberry, sugared jasmine, crystal muguet, pink patchouli and sheer woods, the limited-edition eau de parfum was crafted with the highest fragrance load in the Bath & Body Works portfolio, creating a rich and long-lasting fragrance experience. Presented in an individually numbered bottle, the limited-edition eau de parfum is designed as both a fragrance and collectible keepsake, complete with a removeable bow charm, embellished with Swarovski Crystals, extending the experience beyond the fragrance itself.

In a nod to the fragrance’s a thousand wishes inspiration, only 1,000 individually numbered bottles were created. The limited-edition fragrance will launch on 11/11, a date chosen to reinforce the collection’s wish-inspired storytelling. A Thousand Crystal Wishes will be available through Bath & Body Works Drops and at select stores.

Celebrating the Magic of a Wish: Introducing A Thousand Wishes Muse Valentina Ferrer

Brought to life through a holiday campaign starring global fashion icon and A Thousand Wishes muse Valentina Ferrer, the collection celebrates the optimism, possibility and joy that have defined the fragrance since 2014, while introducing its signature spirit to a new generation around the world.

Inspired by the idea that every wish holds possibility, the campaign captures Ferrer through a world of light, reflection and celebration, showcasing the optimism and wonder that have long defined A Thousand Wishes. Through imagery of water and movement, the creative highlights the transformative power of making a wish and embracing what comes next.

“There’s something beautiful about making a wish. It’s a moment where you allow yourself to dream without limits and imagine everything that could be ahead of you,” said Ferrer. “A Thousand Wishes by Bath & Body Works captures a sense of optimism and celebration, which makes it feel especially fitting during the holidays when you’re reflecting on wishes, dreams and the moments that matter most.”

The campaign will debut during the Latin GRAMMY Awards, including a Spanish-language adaptation of the creative, and will appear across social media, YouTube and digital platforms throughout the holiday season.

Availability

A Thousand Wishes

• Available now at Bath & Body Works stores nationwide and online at bathandbodyworks.com.
• Available now at Ulta Beauty stores nationwide and online at Ulta.com.
• Available now on Amazon.
• Available throughout the United States and Canada.
• Products range from approximately $13 to $70.

A Thousand Wishes Granted

• Available on Amazon beginning November 16.
• Available throughout the United States and Canada.
• Products range from approximately $13 to $70.

A Thousand Crystal Wishes

• Available exclusively through Bath & Body Works Drops and in select Bath & Body Works stores.
• Available in the United States.

Looking Ahead

• The A Thousand Wishes franchise is expected to expand internationally beginning in spring 2027.

ABOUT BATH & BODY WORKS

Bath & Body Works is a global leader in personal care and home fragrance, driven by the belief that everybody deserves to feel good.

The brand’s beloved scents are expertly crafted for performance and a luxury fragrance experience. Formulated with thoughtfully chosen ingredients, Bath & Body Works body care products are available in multiple forms, including fine fragrance mist, body cream, lotion, eau de parfum, body wash, hand soap, sanitizer and more. The brand’s 3-wick candles are made with high-quality fragrance oils layered throughout a premium soy wax base for up to 45 hours of room-filling fragrance.

Consumers can shop Bath & Body Works in more than 1,900 stores in the U.S. and Canada, 550-plus international locations and select Ulta Beauty stores. Online, consumers can visit bathandbodyworks.com, Amazon and Ulta.com.

*Based on review of independent testing by board-certified dermatologist

MEDIA CONTACT
communications@bbw.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3777fec3-90e6-4626-9763-3a4fe4f13a00

NESS ZIONA, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today issued a reminder, further to its announcement dated September 30, 2026, regarding the voluntary delisting of its ordinary shares, no par value per share (the “Ordinary Shares”), from trading on the Tel Aviv Stock Exchange Ltd. (“TASE”). The Company encourages holders of Ordinary Shares traded on the TASE to contact their banks or brokers to arrange for the conversion of their Ordinary Shares into American Depositary Shares (“ADSs”).

As previously announced, the last day of trading of the Ordinary Shares on the TASE will be January 1, 2027, and the Ordinary Shares will be delisted from the TASE on January 4, 2027.

The Company’s ADSs, each currently representing ninety (90) Ordinary Shares, will continue to be listed and trade on the Nasdaq Capital Market (“Nasdaq”), under the symbol “FRSX.” The voluntary delisting from the TASE will not affect the Company’s listing on Nasdaq or its reporting obligations under U.S. securities laws.

The Bank of New York Mellon (“BNY”), the depositary for the Company’s ADS program, will waive its issuance fees for the conversion of Ordinary Shares into ADSs through January 7, 2027. Beginning January 8, 2027, BNY will charge issuance fees of $5.00 per 100 ADSs delivered or a fraction thereof. The waiver applies only to BNY’s issuance fees; shareholders should consult their banks or brokers regarding any other applicable fees or charges.

A conversion guide prepared by BNY, including custodian details, required delivery instructions, issuance fees and settlement procedures, is available on the Company’s website at https://ir.foresightauto.com/wp-content/uploads/2026/11/Foresight-Conversion-Guide-Shares-to-ADSs.pdf.

Shareholders are encouraged to review the guide and contact their banks or brokers promptly to allow sufficient time to complete the conversion and benefit from BNY’s fee waiver.

To convert Ordinary Shares into ADSs, shareholders should instruct their banks or brokers to deposit the Ordinary Shares with one of BNY’s Israeli custodians identified in the conversion guide and provide complete delivery instructions. Deposits must result in the issuance of whole ADSs; deposits resulting in fractional ADSs will be rejected by the custodians.

Shareholders should confirm in advance that their receiving broker is able to accept delivery of the ADSs through The Depository Trust Company (“DTC”). Unless the Company makes special arrangements with BNY, deliveries after January 7, 2027, will be made on a delivery-versus-payment basis for the applicable issuance fees. The receiving DTC broker must accept delivery and payment of those fees for settlement to be completed.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional (3D) perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd., and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of-sight” accident-prevention solutions.

Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment, and UAVs.

Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on X, or join Foresight Automotive on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “aims,” “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the voluntary delisting from the TASE, the last trading day and delisting date of the Ordinary Shares on the TASE, the continued listing and trading of the ADSs on Nasdaq, and the anticipated arrangements for conversion of Ordinary Shares into ADSs, including BNY’s issuance fee waiver and subsequent issuance fees and settlement procedures. Because such statements deal with future events and are based on Foresight’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Foresight’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the content of third party websites.

Investor Relations Contact:
Miri Segal-Scharia
CEO
MS-IR LLC
msegal@ms-ir.com

^{All financial figures are in Canadian dollars unless otherwise noted}

CALGARY, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Gibson Energy Inc. (TSX:GEI) (“Gibson”, or the “Company”) announced today that its Board of Directors has approved a quarterly dividend of $0.45 per common share, payable on January 15, 2027, to shareholders of record at the close of business on December 30, 2026. This dividend is designated as an eligible dividend for Canadian income tax purposes. For non-resident shareholders, Gibson’s dividends are subject to Canadian withholding tax.

About Gibson
Gibson is a leading liquids infrastructure company providing storage, optimization, processing, gathering, and waterborne vessel loading services for liquids and refined products. Headquartered in Calgary, Alberta, the Company’s operations are located across North America, with core terminal assets in Hardisty and Edmonton, Alberta, Ingleside and Wink, Texas, and a facility in Moose Jaw, Saskatchewan.

Gibson shares trade under the symbol GEI and are listed on the Toronto Stock Exchange. For more information, visit www.gibsonenergy.com.

For further information, please contact:

Investor Relations
Phone: (403) 776-3077
Email: investor.relations@gibsonenergy.com

Media
Phone: (403) 476-6334
Email: communications@gibsonenergy.com

Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board

Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the appointment by way of co-optation of Dr. Mehdi Shahidi as Non-Executive Independent Director to its Board of Directors, effective November 2, 2026. He replaces Dr. Paulo Fontoura, who resigned from the Board in July 2026 following his appointment as the Global Head of R&D at Sanofi SA.

“We are thrilled to welcome Mehdi to the Board. I’m confident his extensive experience in drug development, history of regulatory success, and track record of building organizations will strengthen the Board’s ability to provide strategic guidance to Lakefront as it continues to advance gamgertamig and its preclinical assets, while maintaining a disciplined approach to deploying its strategic capital,” said Gino Santini, Chair of the Board of Directors.

Biography
Dr. Mehdi Shahidi is a physician-scientist and an accomplished drug development and R&D leader with over 20 years of biopharma experience spanning translational research, clinical development, regulatory and successful introduction of innovative medicines to patients worldwide. His career combines senior leadership in global pharmaceutical R&D with entrepreneurial, venture capital, and board-level experience. He is currently Head of Development and Chief Medical Officer at Ottimo Pharma, Venture Partner at Medicxi, and a founder of Petalion Therapeutics. Previously, Dr. Shahidi served as SVP, Global Head of Medicine and CMO at Boehringer Ingelheim, where he led a large, global organization with a broad therapeutic mandate. During his tenure, he provided strategic and scientific oversight across a diverse portfolio of drug development programs, from early clinical development through multiple successful global regulatory approvals across various therapeutic areas. Dr. Shahidi previously served on the Supervisory Board of CureVac through its acquisition by BioNTech, as well as on the Innovation Committees of EFPIA and TransCelerate and the PhRMA R&D Leadership Forum. A clinical oncologist and GMC-registered specialist in pharmaceutical medicine, Dr. Shahidi completed his oncology training at the Royal Marsden Hospital and conducted clinical research at the Institute of Cancer Research, London.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations

Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

Forward-looking statements
This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as “will,” “long-term,” and “forward,” and any similar expressions. These statements include, but are not limited to, statements regarding the appointment of a new director, the expected benefits associated with the changes to Lakefront’s Board, and Lakefront’s ability to deliver meaningful impact for patients and sustainable value for shareholders. Any forward-looking statements in this press release are based on Lakefront’s management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties and other factors which might cause Lakefront’s actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties and other factors include, without limitation, the risk that Lakefront may not be able to realize the expected benefits from the appointment of the new director. A further list and description of these risks, uncertainties and other factors can be found in Lakefront’s filings and reports with the Securities and Exchange Commission (SEC), including in Lakefront’s most recent annual report on Form 20-F filed with the SEC, as supplemented and/or modified by any other filings and reports that Lakefront has made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if Lakefront’s results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. Lakefront expressly disclaims any obligation to update any forward-looking statements in this press release, unless required by law or regulation.

Attachment

• Nov 2026 New Board Member_vF_EN

– Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition –

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions.

Current Chief Financial Officer Keith A. Goldan has decided to retire from the position and will remain with the Company through the end of 2026 to support the transition. Mr. Goldan led Syndax’s financial and capital strategy during an important period in the Company’s history. He played a key role in the successful launches of Revuforj and Niktimvo and in initiatives that strengthened the Company’s pipeline and innovative R&D platform.

“On behalf of the Board and our entire team, I thank Keith for his many valuable contributions and wish him all the best in his well-earned retirement,” said Michael A. Metzger, Chief Executive Officer of Syndax. “Keith was integral to Syndax’s transition into a commercial-stage company and the delivery of three FDA approvals, and he helped lay the foundation for our long-term success.”

Mr. Metzger continued, “We are delighted to welcome Aaron to Syndax. He brings decades of experience guiding biopharma companies through commercial expansion and major milestones. The Board and I are confident he will successfully lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value.”

“I am thrilled to join Syndax at such a pivotal moment in the Company’s evolution,” said Aaron A. Ondrey. “Syndax has built an impressive commercial platform with two approved medicines and a compelling pipeline targeting significant market opportunities. I look forward to partnering with Michael and the broader Syndax team to build on the Company’s leadership position and its strong financial foundation.”

“It has been a privilege to serve as CFO at Syndax and partner with Michael and a highly talented and dedicated team,” said Keith A. Goldan, Chief Financial Officer of Syndax. “I am proud of everything we have accomplished together and the positive impact this work continues to have for patients. I am confident Syndax is well positioned for continued success long into the future.”

Mr. Ondrey brings extensive leadership and financial experience across both pre-commercial and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Beren Therapeutics, where he oversaw finance, investor relations, and manufacturing operations. Prior to joining Beren Therapeutics, Mr. Ondrey served as Chief Financial Officer of Rocket Pharmaceuticals, where he led the company’s financial strategy as it prepared for its transition to a commercial-stage organization. Before Rocket Pharmaceuticals, he was Chief Financial Officer and Senior Vice President at Mirati Therapeutics, where he supported the commercialization of KRAZATI® and played a key role in the company’s acquisition by Bristol Myers Squibb in January 2024. Earlier in his career, Mr. Ondrey held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals, building extensive experience in corporate finance, strategic planning, commercialization, and operational execution.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the acceptance of Syndax and its partners’ products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj’s or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G